We’ve been pounding the table over coronavirus face mask and vaccine stocks for weeks.
- Alpha Pro Tech (APT) now run from $14.09 to $19.90
- Moderna (MRNA) just ran to $66.84 from around $63
- Teladoc Health (TDOC) ran from $191.89 to $198
- Inovio Pharmaceuticals (INO) just ran from $21.37 to $26
All because the coronavirus just won’t die.
Hundreds of thousands of people are being infected by the day. Thousands have died. There are even fears global economies may need to be shut down again.
The world is in desperate need for treatment — anything to halt the spread.
The good news is we may be nearing a possible solution from companies like Novavax (NVAX).
After all, the virus is still here – and it’s only getting worse.
Johns Hopkins University is warning of another severe breakout.
“There is a new wave coming in parts of the country,” Eric Toner, a senior scholar for Health Security said, as quoted by Bloomberg. “It’s small and it’s distant so far, but it’s coming.”
There are flare-ups in Alaska, Arkansas, Florida Kentucky, Mississippi, North Carolina, Oregon, South Carolina, and Utah. Phoenix Mayor Kate Gallego even just admitted, “We opened too much too early and so our hospitals are really struggling.”
At the moment, NVAX is racing to higher highs after being awarded a contract by the U.S. Department of Defense (DoD) for the manufacturing of NVX‑CoV2373, Novavax’ COVID-19 vaccine candidate. NVX‑CoV2373 consists of a stable, prefusion protein antigen made using its proprietary nanoparticle technology and includes Novavax’ proprietary Matrix‑M adjuvant.
“JPEO-CRBND-EB through funding provided by the Defense Health Program, has agreed to fund up to $60 million to support Novavax in its production of several components of the vaccine that will be manufactured in the U.S. The agreement includes a 2020 delivery of 10 million doses of NVX‑CoV2373 for DoD that could be used in Phase 2/3 clinical trials or under an Emergency Use Authorization (EUA) if approved by the U.S. FDA,” according to a NVAX PR.